US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as Bavencio by its original developer Merck ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

The Call of Kinnaru and Visiting Professor of Classics Marissa Henry took to the stage last Thursday for a performance of ...

LARKSPUR, Calif., March 25, 2025--(BUSINESS WIRE)--Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics ...